PDCD1 and intrahepatic cholangiocarcinoma: The significance of our research is that it not only provides a biomarker to predict the prognosis of ICC patients and assay the tumor response to anti-PD1 immunotherapy, but it also provides a new immunotherapeutic strategy for ICC with different risk factors.